PDCD1 and non-small cell lung carcinoma: The only PARP7 inhibitor currently in clinical trials, RBN-2397, is being tested for treating non-small cell lung cancer (NSCLC) in combination with pembrolizumab (clinical trial ID NCT05127590; https://clinicaltrials.gov/study/NCT05127590), a monoclonal antibody that blocks the PD-1 immune checkpoint receptor (also known as PDCD1), thereby enhancing T cell-mediated immune responses against tumors.